Evaluation of Homology Modeling of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Main Protease for Structure Based Drug Design

• Takeda-Shitaka Mayuko

  School of Pharmaceutical Sciences, Kitasato University

• Nojima Hiroyuki

  School of Pharmaceutical Sciences, Kitasato University

• Takaya Daisuke

  School of Pharmaceutical Sciences, Kitasato University

• Kanou Kazuhiko

  School of Pharmaceutical Sciences, Kitasato University

• Iwadate Mitsuo

  School of Pharmaceutical Sciences, Kitasato University

• Umeyama Hideaki

  School of Pharmaceutical Sciences, Kitasato University

抄録

To accelerate the development of drugs against severe acute respiratory syndrome (SARS), we constructed a homology model of the SARS coronavirus main protease using our modeling software, FAMS Ligand&Complex, and released it before the X-ray structure was solved. The X-ray structure showed our model as accurately predicted and useful for structure based drug design.

収録刊行物

• ＣＨＥＭＩＣＡＬ　＆　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ　ＢＵＬＬＥＴＩＮ

  ＣＨＥＭＩＣＡＬ　＆　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ　ＢＵＬＬＥＴＩＮ 52 (5), 643-645, 2004

  公益社団法人 日本薬学会

キーワード

• homology modeling
• severe acute respiratory syndrome (SARS)
• normal mode analysis
• structure based drug design

詳細情報

• CRID: 1390001204171569152
• NII論文ID: 110003615633
• NII書誌ID: AA00602100
• DOI: 10.1248/cpb.52.643
• ISSN: 13475223
• ISSN: 00092363
• NDL書誌ID: 6931570
• PubMed: 15133227
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I6931570
• Web Site: http://www.jstage.jst.go.jp/article/cpb/52/5/52_5_643/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2005000536
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可